



Timing of implant-removal in late acute periprosthetic joint infection: A multicenter observational study



Marjan Wouthuyzen-Bakker^{a,*}, Marine Sebillotte^b, Jose Lomas^c, Benjamin Kendrick^c, Eva Benavent Palomares^d, Oscar Murillo^d, Javad Parvizi^e, Noam Shohat^{e,f}, Javier Cobo Reinoso^g, Rosa Escudero Sánchez^g, Marta Fernandez-Sampedro^h, Eric Sennevilleⁱ, Kaisa Huotari^j, José Maria Barbero Allende^k, Antonio Blanco García^l, Jaime Lora-Tamayo^m, Matteo Carlo Ferrariⁿ, Danguole Vaznaiciene^o, Erlangga Yusuf^p, Craig Aboltins^{q,r}, Rihard Trebse^s, Mauro José Salles^t, Natividad Benito^u, Andrea Vila^v, Maria Dolores Del Toro^w, Tobias Siegfried Kramer^{x,y}, Sabine Petersdorf^z, Vicens Diaz-Brito^{aa}, Zeliha Kocak Tufan^{ab}, Marisa Sanchez^{ac}, Cédric Arvieux^{b,ad}, Alex Soriano^{ae}, on behalf of the ESCMID Study Group for Implant-Associated Infections (ESGIAI)

^a Department of Medical Microbiology and Infection Prevention, University of Groningen, University Medical Center Groningen, Hanzplein 1, 9713 GZ, Groningen, the Netherlands

^b Department of Infectious Diseases and Intensive Care Medicine, Rennes University Hospital, Rennes, France

^c Bone Infection Unit, Nuffield Orthopaedic Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, England

^d Infectious Disease Service, IDIBELL-Hospital Universitari Bellvitge, Barcelona, Spain

^e Rothman Institute at Thomas Jefferson University Hospital, Philadelphia, United States

^f Department of Orthopaedic Surgery, Tel Aviv University, Tel Aviv, Israel

^g Servicio de Enfermedades Infecciosas, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain

^h Infectious Diseases Unit, Department of Medicine, Hospital Universitario Marques de Valdecilla-IDIVAL, Cantabria, Spain

ⁱ Department of Infectious Diseases, University Hospital Gustave Dron Hospital, Tourcoing, France

^j Inflammation Center, Infectious Diseases, Peijas Hospital, Helsinki University Hospital and University of Helsinki, Finland

^k Department of Internal Medicine, Hospital Universitario Príncipe de Asturias, Madrid, Spain

^l Department of Internal Medicine-Emergency, IIS-Fundación Jiménez Díaz, UAM, Av. Reyes Católicos 2, 28040 Madrid, Spain

^m Department of Internal Medicine, Hospital Universitario 12 de Octubre, Instituto de Investigación i+12, Madrid, Spain

ⁿ Department of Prosthetic Joint Replacement and Rehabilitation Center, Humanitas Research Hospital and Humanitas University, Milan, Italy

^o Department of Infectious Diseases, Medical Academy, Lithuanian University of Health Sciences, Kaunas Clinical Hospital, Kaunas, Lithuania

^p Department of Microbiology, Antwerp University Hospital (UZA), University of Antwerp, Edegem, Belgium

^q The Department of Infectious Diseases, Northern Health, Melbourne, Australia

^r Northern Clinical School, The University of Melbourne, Melbourne, Australia

^s Service for Bone Infections, Valdoltra Orthopaedic Hospital, Ankarana, Slovenia

^t Santa Casa de São Paulo School of Medical Sciences, São Paulo, Brasil

^u Infectious Diseases Unit, Department of Internal Medicine, Hospital de la Santa Creu i Sant Pau, Institut d'Investigació Biomèdica Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain

^v Servicio de Infectología, Hospital Italiano de Mendoza, Mendoza, Argentina

^w Unidad Clínica de Enfermedades Infecciosas y Microbiología, Universidad de Sevilla, Instituto de Biomedicina de Sevilla (IBIS), Sevilla, Spain

^x Nationales Referenzzentrum für Surveillance von nosokomialen Infektionen am Institut für Hygiene und Umweltmedizin Charité-Universitätsmedizin, Berlin, Germany

^y LADR, GmbH MVZ, Neuruppin, Germany

^z Institute of Medical Microbiology, Hospital Hygiene University Hospital, Heinrich-Heine-University, Düsseldorf, Germany

^{aa} Infectious Diseases Unit, Parc Sanitari Sant Joan de Deu, IDIBAPS, Sant Boi, Barcelona, Spain

^{ab} Infectious Diseases and Clinical Microbiology Department, Ankara Yıldırım Beyazıt University, Atatürk Training & Research Hospital, Ankara, Turkey

^{ac} Infectious Diseases Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Argentina

^{ad} Great West Reference centers for Complex Bone and Joint Infections (CRIOGO), France

^{ae} Service of Infectious Diseases, Hospital Clínic, University of Barcelona, Barcelona, Spain

* Corresponding author.

E-mail address: m.wouthuyzen-bakker@umcg.nl (M. Wouthuyzen-Bakker).

ARTICLE INFO

Article history:

Accepted 5 July 2019

Available online 15 July 2019

Keywords:

Periprosthetic joint infection

Late acute

Hematogenous

Debridement

Revision surgery

Failure

SUMMARY

Objectives: We evaluated the treatment outcome in late acute (LA) periprosthetic joint infections (PJI) treated with debridement and implant retention (DAIR) versus implant removal.

Methods: In a large multicenter study, LA PJIs of the hip and knee were retrospectively evaluated. Failure was defined as: PJI related death, prosthesis removal or the need for suppressive antibiotic therapy. LA PJI was defined as acute symptoms <3 weeks in patients more than 3 months after the index surgery and with a history of normal joint function.

Results: 445 patients were included, comprising 340 cases treated with DAIR and 105 cases treated with implant removal (19% one-stage revision ($n=20$), 74.3% two-stage revision ($n=78$) and 6.7% definitive implant removal ($n=7$). Overall failure in patients treated with DAIR was 45.0% (153/340) compared to 24.8% (26/105) for implant removal ($p < 0.001$). Difference in failure rate remained after 1:1 propensity-score matching. A preoperative CRIME80-score ≥ 3 (OR 2.9), PJI caused by *S. aureus* (OR 1.8) and implant retention (OR 3.1) were independent predictors for failure in the multivariate analysis.

Conclusion: DAIR is a viable surgical treatment for most patients with LA PJI, but implant removal should be considered in a subset of patients, especially in those with a CRIME80-score ≥ 3 .

© 2019 The British Infection Association. Published by Elsevier Ltd. All rights reserved.

Introduction

A periprosthetic joint infection (PJI) is a serious complication after joint arthroplasty and is accompanied by increased morbidity and mortality.^{1,2} Clinical outcome is highly dependent on host related factors, clinical characteristics, the causative microorganism, and the applied antimicrobial therapy and surgical techniques.^{4,10,11} Therefore, optimizing treatment and composing tailored strategies are crucial to improve clinical outcome. We recently demonstrated that late acute PJIs have a relatively high failure rate when treated with surgical debridement and implant retention (DAIR).²¹ Failure seems to be most prominent when the infection is caused by *Staphylococcus aureus*, with reported failures of around 50%, which is higher than described for early acute/post-surgical PJIs.^{13,17,19–21} Moreover, several preoperative variables, defined according to the CRIME80-score (i.e. **C**-reactive protein >150 mg/L, **C**hronic obstructive pulmonary disease, **R**heumatoid arthritis, fracture as **I**ndication for the prosthesis, **M**ale gender, not **E**xchanging the mobile components during debridement and an age above **80** years), expose patients to a higher failure risk as well.²¹ Despite the relatively high failure rate, a DAIR procedure is still recommended as the first line surgical approach for all acute PJIs if the implant is well fixed and if anti-biofilm antibiotics can be applied.¹⁵ However, revision of the prosthetic implant might be a better treatment modality in a subset of patients with late acute infections.¹⁷ For this reason, we compared the clinical outcome of patients with a late acute PJI treated with DAIR or immediate implant removal in a large multicenter observational cohort study and identified those patients who may benefit more from implant removal instead of DAIR. Propensity score matching was applied to correct for selection bias between both surgical techniques.

Material and methods

Study design and inclusion criteria

We performed an international multicenter retrospective observational study in which data of all consecutive patients with a late acute PJI of the hip or knee between January 2005 and December 2015 were collected. If centers were not able to provide cases during the complete study period, a minimum of at least 10 consecutive cases was required to participate in the study. Late acute PJI was defined as patients with a history of normal joint function and who developed a sudden onset of symptoms and signs of a PJI, such as acute pain and/or swelling of the prosthetic joint. Patients with symptoms existing for longer than 3 weeks before surgical treatment was applied, patients who were within 3 months after

the index arthroplasty, patients with a sinus tract and patients in whom antibiotic suppressive therapy was prescribed after surgery for other reasons than persistent signs of infection (e.g. because this was routine practice of the participating hospital and/or because the patient had severe comorbidity and was therefore, not eligible for future surgeries) were excluded from the analysis. PJI was defined according to the diagnostic criteria described by the Musculoskeletal Infection Society (MSIS).¹⁶ Multiple variables on patient characteristics, clinical presentation, microbiology results, surgical and antibiotic treatment and outcome were collected and analyzed. Patients treated with DAIR comprised the same cohort as described in our previous study.²¹ Informed consent was retrieved when required by the ethics committee of the participating center.

Clinical outcome

Failure was defined as: (i) the need for prosthesis removal due to persistent or recurrent signs of infection in the DAIR group or removal of the revised prosthesis in the removal group (ii) the need for suppressive antibiotic therapy because of persistent clinical or biochemical signs of infection, (iii) death due to the infection. The need for additional surgical debridement or spacer exchange in case of two-stage revisions was not considered as failure, but as part of the procedure. *Complete remission* was defined as a functional implant at the last follow-up, which was defined as the ability to walk without pain and the absence of clinical or biochemical signs of persistent infection.

Debridement and implant retention versus implant removal

The surgical techniques of the DAIR procedure, one-stage and two-stage revision surgery are extensively described in literature.^{3,10} In brief, in case of a DAIR procedure, visibly infected and necrotic tissue is excessively debrided, the wound is thoroughly irrigated using three to six liters of saline and mobile components are exchanged if possible. The same holds for a one-stage procedure, with the addition that the whole prosthesis is removed and exchanged for a new implant. Subsequent antimicrobial therapy is prescribed for a minimum of six weeks, but a duration of three months of antibiotics is most often applied for both procedures. During a two-stage procedure, the prosthesis is removed in the first stage and in most cases temporarily replaced by a cemented spacer loaded with antibiotics. Subsequent antimicrobial therapy is prescribed for a minimum of six weeks. In the second surgery, the new prosthesis is reimplanted during or after finishing antibiotic therapy for the initial infection. The applied antibiotic regimens in this study are depicted in Supplementary Table 1.

Table 1

Patient characteristics late acute prosthetic joint infection (PJI) treated with surgical debridement and implant retention (DAIR) [$n = 340$] versus implant removal [$n = 105$] (1-stage revision ($n = 20$), 2-stage revision ($n = 78$) or definitive removal of the implant ($n = 7$)).

	Total patient group			Propensity score matching 1:1		
	Implant retention ($n = 340$)	Implant removal ($n = 105$)	<i>p</i> -value	Implant retention ($n = 81$)	Implant removal ($n = 81$)	<i>p</i> -value
Baseline characteristics						
Gender, male	51.5% (175/340)	42.9% (45/105)	0.12	50.6% (41/81)	42.0% (34/81)	0.27
Age > 80 years ^c	21.5% (73/340)	20.0% (21/105)	0.75	19.8% (16/81)	22.2% (18/81)	0.70
BMI > 30	48.9% (110/225)	41.8% (28/67)	0.31	50.0% (25/50)	41.2% (21/51)	0.37
ASA classification \geq III	48.6% (140/288)	44.4% (36/81)	0.51	47.1% (33/70)	42.6% (26/61)	0.60
Medical history						
Hypertension	59.6% (202/339)	61.9% (65/105)	0.67	64.2% (52/81)	61.7% (50/81)	0.67
Ischemic heart disease	12.1% (41/340)	8.6% (9/105)	0.32	8.6% (7/81)	7.4% (6/81)	0.77
Heart failure	9.1% (31/339)	6.7% (7/105)	0.43	2.5% (2/81)	3.7% (3/81)	0.65
Diabetes Mellitus	25.0% (85/340)	22.9% (24/105)	0.58	17.3% (14/81)	22.2% (18/81)	0.43
COPD ^c	10.0% (34/340)	14.3% (15/105)	0.22	4.9% (4/81)	13.6% (11/81)	0.06
Chronic renal insufficiency	7.6% (26/340)	11.4% (12/105)	0.23	6.2% (5/81)	6.2% (5/81)	1.0
Liver cirrhosis	3.2% (11/340)	6.7% (7/105)	0.12	6.2% (5/81)	3.7% (3/81)	0.47
Active malignancy	8.5% (29/340)	2.9% (3/105)	0.05	2.5% (2/81)	3.7% (3/81)	0.65
Rheumatoid arthritis ^c	7.9% (27/340)	5.7% (6/105)	0.45	8.6% (7/81)	7.4% (6/81)	0.77
Medication						
Oral anticoagulant	18.2% (61/336)	10.7% (11/103)	0.07	16.0% (13/81)	8.9% (7/79)	0.17
Immune-suppressive drugs	11.5% (39/340)	7.6% (8/105)	0.26	11.1% (9/81)	9.9% (8/81)	0.80
Characteristics infected implant						
Knee	72.6% (247/340)	57.1% (60/105)	0.003	65.4% (53/81)	61.7% (50/81)	0.62
Indication prosthesis: fracture ^c	5.4% (17/313)	6.9% (7/101)	0.58	5.4% (4/81)	9.1% (7/81)	0.38
Revision prosthesis	28.4% (96/338)	32.4% (33/102)	0.44	30.9% (25/81)	31.6% (25/79)	0.92
Tumor prosthesis	4.3% (14/326)	4.9% (5/103)	0.81	3.9% (3/76)	3.8% (3/79)	0.96
Cemented stem	75.3% (186/247)	58.3% (49/84)	0.003	70.7% (41/58)	60.6% (40/66)	0.24
Age of the implant > 2 years	63.5% (216/340)	61.9% (65/281)	0.76	53.1% (43/81)	60.5% (49/81)	0.34
Clinical presentation						
Duration of symptoms > 10 days	20.9% (71/340)	30.5% (32/105)	0.04	22.2% (18/81)	18.4% (23/81)	0.37
Temperature > 38.5 °C	21.3% (70/329)	5.9% (6/101)	< 0.001	16.9% (13/77)	6.5% (5/77)	0.05
Physical signs of inflammation	81.5% (264/324)	79.4% (81/102)	0.64	79.7% (59/74)	79.5% (62/78)	0.97
CRP > 150 mg/L ^c	60.4% (194/321)	53.2% (50/94)	0.21	60.0% (45/75)	59.2% (42/71)	0.92
Leucocytes > 17 cells/ μ L	14.5% (46/317)	17.3% (18/104)	0.49	21.1% (16/76)	15.0% (12/80)	0.33
Bacteremia ^a	32.2% (109/339)	30.5% (32/105)	0.75	32.1% (26/81)	30.9% (25/81)	0.87
Endocarditis	3.8% (13/340)	3.8% (4/105)	1.0	2.5% (2/81)	2.5% (2/81)	1.0
Source identified	45.9% (156/340)	33.7% (35/104)	0.03	37.0% (30/81)	38.8% (31/80)	0.82
Identified micro-organism						
<i>Staphylococcus aureus</i>	41.5% (141/340)	43.8% (46/105)	0.67	43.2% (35/81)	43.2% (35/81)	1.0
– Methicillin resistant	5.6% (19/340)	8.6% (9/105)	0.27	7.4% (6/81)	7.4% (6/81)	1.0
<i>Enterococcus</i> species	3.2% (11/340)	8.6% (9/105)	0.02	3.7% (3/81)	9.9% (8/81)	0.12
<i>Streptococcus</i> species	28.5% (97/340)	16.2% (17/105)	0.01	25.9% (21/81)	16.0% (13/81)	0.12
Gram negative rods	14.7% (50/340)	11.4% (12/105)	0.40	14.8% (12/81)	12.3% (10/81)	0.65
Outcome						
Overall failure	45.0% (153/340)	24.8% (26/105)	< 0.001	51.9% (42/81)	25.9% (21/81)	0.001
Failed cases						
– Need for implant removal	35.9% (55/153)	30.8% (8/26)	0.61	43.9% (18/42)	38.1% (8/21)	0.66
– Relapse of infection during FU	33.3% (51/153)	11.5% (3/26)	0.03	29.3% (12/42)	9.5% (2/21)	0.08
– Reinfection during FU	7.8% (12/153)	38.5% (10/26)	< 0.001	12.2% (5/42)	42.9% (9/21)	0.006
– Need for suppressive therapy	15.7% (24/153)	0% (0/26)	0.03	9.8% (4/42)	0.0% (0/21)	0.14
– Death due to PJI	7.2% (11/153)	19.2% (5/26)	0.05	4.9% (2/42)	9.5% (2/21)	0.48
Overall PJI related death	3.2% (11/340)	4.8% (5/105)	0.52	2.5% (2/81)	2.5% (2/81)	1.0
Complete remission in non-failures ^b	86.1% (155/180)	84.3% (64/75)	0.87	81.1% (30/37)	87.5% (49/56)	0.40

^a Patients in whom no blood cultures were obtained were considered as blood culture negative cases.

^b Defined as: patients with a retained and pain-free implant at the last follow-up.

^c Preoperative risk factors for failure in late acute PJI according to the CRIME80 score (6). BMI: Body Mass Index, ASA: American Society of Anesthesiologist, COPD: Chronic Obstructive Pulmonary Disease, CRP: C-Reactive Protein.

Statistical analysis

A Chi-square test (or a Fisher exact-test when appropriate) was used to analyze the difference between groups for categorical variables, and a student *t*-test (or Mann Whitney *U* test when data was not normally distributed) for continuous variables. A Kaplan Meier survival curve with a Cox-regression analysis was used to evaluate failure rate in time. To correct for bias between the DAIR group versus the implant removal group, a propensity score matching was performed. A propensity score was calculated using a logistic regression model in which the surgical strategy was used as the dependent variable, and variables that were significantly different between the implant retention group and the implant

removal group as covariates. Matching was performed using a caliper of two decimals, and identical scores were randomized to perform the matching. Chi-square testing was performed to analyze the difference in outcome between both surgical approaches (implant retention versus implant removal). Univariate analysis using Pearson correlation was performed for determining risk factors for failure. Variables with a significance level of < 0.2 were analyzed in a binary multivariate logistic regression model. The propensity score for DAIR was included in the model. For all analyses, *p*-values < 0.05 were considered as statistically significant. All analyses were two-tailed. Data were presented as mean \pm Standard Deviation (SD) when data was normally distributed or median \pm Inter Quartile Range (IQR) when data was not normally

Table 2
CRIME80-score, pre-operative risk score for predicting DAIR failure in late acute periprosthetic joint infections.

CRIME80-score Variable	Description	Score
C	COPD	2
	CRP > 150 mg/L	1
R	Rheumatoid Arthritis	3
I	Index surgery (prosthesis indicated for a fracture)	3
M	Male gender	1
E	Exchange of mobile components	-1
80	Age > 80 years	2

distributed. Statistical analysis was performed using SPSS, version 23.0 (SPSS Inc., Chicago, IL).

Results

Patient characteristics implant retention versus implant removal

A total of 445 patients from 27 centers were included in the analysis. Table 1 shows the preoperative differences between patients with late acute PJI treated with DAIR and implant retention ($n=340$) versus patients in whom the implant was removed ($n=105$). In the implant removal group, one-stage revision was performed in 20 cases (19.0%), two-stage revision in 78 cases (74.3%), and definitive implant removal in 7 cases (6.7%) (Girdlestone for hips [$n=5$] and arthrodesis for knees [$n=2$]). Compared to implant removal, debridement with implant retention was performed more often in knee PJIs, cemented prostheses and in patients presenting with fever, a duration of symptoms for less than 10 days and with an identified source of infection. Factors associated with worse outcome in late acute PJIs, like *S. aureus* infections and preoperative risk factors predictive for failure according to the CRIME80-score (Table 2; including C-reactive protein and chronic obstructive pulmonary disease (C), rheumatoid arthritis (R), fracture as indication for the prosthesis (I), male gender (M), not exchanging the mobile components during DAIR (E), and age above 80 years (80)²¹) were similar between both groups.

Clinical outcome implant retention versus implant removal

Table 1 shows the clinical characteristics and failure rate in the implant retention and implant removal group. The overall failure in patients treated with DAIR was 45.0% (153/340) versus 24.8% (26/105) in patients treated with implant removal ($p < 0.001$). There was no difference in failure rate between one-stage versus two-stage revision surgery: 25.0% (5/20) versus 24.4% (19/78), respectively ($p 0.95$). The higher failure rate in the implant retention group was dominated by the need for suppressive therapy because of persistent signs of infection and a relapse of infection during follow-up, while most of the failures in the implant removal group were due to a reinfection with another microorganism and PJI related death. The absolute number of PJI related death did not differ between both groups: 3.2% (11/340) for the implant retention group versus 4.8% (5/105) for the implant removal group, ($p 0.52$). The need for prosthesis removal as a primary endpoint for failure was the same in both groups. The higher failure rate in the implant retention group remained after propensity score matching for all significantly different variables between both groups as depicted in Table 1. We additionally performed a multivariate analysis including all variables with a p -value < 0.2 in the univariate analysis predictive for failure (i.e. the propensity score for DAIR, CRIME80-score ≥ 3 , endocarditis, bacteremia, fever, < 1 year after the index surgery, use of immune suppressive drugs and *S. aureus* PJI). A preoperative CRIME80-score ≥ 3 (OR 2.9, 95% CI 1.7–4.9, $p < 0.001$), a




Fig. 1. Failure rate late acute PJI in patients with a high versus low CRIME80-score (depicted in Table 2) according to the surgical strategy.

PJI caused by *S. aureus* (OR 1.8, 95% CI 1.1–2.9, $p 0.03$) and implant retention (OR 3.1, 95% CI 1.7–5.8, $p < 0.001$) were the only significant independent predictors for failure. Although the exchange of mobile components during DAIR showed a significant decrease in failure rate from 52.4% (77/147) to 36.4% (64/176) ($p 0.004$), it remained significantly higher compared to implant removal (24.8% (26/105) $p 0.04$).

To assess whether the outcome of patients from centers with a high case load differed from the ones with a lower case load, we subdivided centers into 3 groups according to the number of cases they provided: (i) less than 10 cases; (ii) between 10 and 20 cases; (iii) more than 20 cases. 5 centers provides less than 10 (18.5%), 10 centers between 10 and 20 (37.5%) and 12 center more than 20 cases (44%). Overall failure rates were 33.3% (12/36), 38.4% (38/99) and 41.6% (129/310), respectively ($p 0.58$). Failure rates of DAIR were 47.5% (10/21), 45.2% (28/62) and 44.7% (115/257), respectively ($p 0.97$).

Failure rates according to the preoperative CRIME80-score

Fig. 1 shows the failure rate of patients treated with implant retention and implant removal according to the CRIME80-score,²¹ a scoring system that includes several host factors and that can be applied to decide which surgical treatment is preferred when the microorganism is not known prior to surgery. For cases treated with implant removal, the variable 'E' (Exchanging the mobile components) was not taken into account to calculate the score. Variables included in the score were complete in 395 out the 445 cases (88.8%). A high preoperative risk score for DAIR failure defined by a CRIME80-score ≥ 3 , demonstrated a failure rate of 67.9% (53/78) in the DAIR group and a 16.7% failure rate (4/24) in the implant removal group ($p < 0.0001$). No significant difference in failure was observed with a CRIME80-score < 3 (35.8% (78/218) versus 23.9% (16/67), respectively ($p 0.07$).

Failure rates according to the microorganism causing the infection and the possibility to exchange the mobile components

Fig. 2 shows the failure rate in time between the different surgical strategies and causative microorganisms. The overall median follow-up of non-failures was 34 months (IQR 15–55) in the implant retention group versus 20 months (IQR 10–40) in the im-




Fig. 2. Outcome late acute PJI caused by *S. aureus* (A) and other microorganisms (B), knees (C) and hips (D) according to the surgical strategy. Survival is defined as treatment success, as described in the material and method section.

plant removal group (p 0.27). For PJI caused by microorganisms other than *S. aureus*, failure rate was 38.7% (77/199) in the implant retention group versus 23.7% (14/59) in the implant removal group (p 0.04). In the implant retention group, the exchange of mobile components during debridement showed a decrease in failure rate from 47.0% (39/83) to 29.6% (32/108) (p 0.01). When mobile components were exchanged, implant removal did not show any significant benefit in these cases (failure rate 29.6% (32/108) versus 23.7% (14/59), respectively, p 0.41). For PJI caused by *S. aureus*, failure rate was 53.9% (76/141) in the implant retention group versus 26.1% (12/46) in the implant removal group (p 0.001). The addition of rifampin in *S. aureus* PJI decreased failure rates from 65.2% (15/23) to 50.4% (57/113) (p 0.20). In patients with *S. aureus* PJI in whom the mobile components were exchanged had a failure rate of 47.1% (32/68) (p 0.02, compared to implant removal 26.1% (12/46)), and further decreased to 36.6% (15/41) when patients were subsequently treated with a fluoroquinolone in combination with rifampin. Within this group, failure rate was not statistically significantly different compared to implant removal (36.6% versus 26.1%, p 0.29). The difference between failure rates according to the surgical strategy was the same for hips and knees (Fig. 2(c) and (d)).

Proposed surgical treatment algorithm

Based on our analyses, we propose a surgical treatment algorithm based on the CRIME80-score, the microorganism causing the infection and its susceptibility pattern (when available prior to surgery) to decide whether revision surgery instead of a DAIR procedure should be considered as first surgical treatment approach (Fig. 3). According to this algorithm, a DAIR procedure is advised when the failure rate of DAIR is $\leq 50\%$, revision surgery should be considered if the failure rate of DAIR is $> 50\text{--}65\%$, and revision surgery is advised when the failure rate of DAIR exceeds 65%. Because the microorganism causing the infection is mostly not known prior to surgery, we first subdivided patients according to their preoperative risk score for DAIR failure (Table 2). However, if the microorganism and its susceptibility to antibiotics are identified, a DAIR procedure maybe a viable treatment option in an additional subset of patients, especially in those infections caused

by *S. aureus* in whom the mobile components can be exchanged and an antibiotic regimen of rifampin plus a fluoroquinolone can be administered (Fig. 3).

Functional outcome in non-failures

Complete remission with a pain-free implant at the last point of follow-up was achieved in 85.9% of the non-failures. In the non-failure group, there was no difference in complete remission between the implant retention group and the implant removal group (Table 1). From the patients in the implant retention group who failed debridement and finally needed revision surgery ($n=55$), follow-up data was available in 41 cases (74.5%). During the last follow-up visit, 63.4% of these cases (26/41) had complete remission with a pain-free implant, while this was 84.3% (64/75) for patients in whom revision surgery was applied as a first surgical approach (p 0.007). There was no difference in functional outcome after revision surgery between cemented and uncemented prostheses (pain-free implant in 82.9% (29/35) versus 89.7% (26/29), respectively, p 0.44).

Discussion

Current international guidelines still recommend a DAIR procedure for all acute PJIs when the implant is well fixed and an antibiotic regimen potent against biofilm infection can be administered.¹⁵ However, it is important to identify patients who have a high risk for DAIR failure prior to surgery in order to select the best surgical option. In line with this, using the same cohort of patients, we recently defined a preoperative risk score (CRIME80-score) to identify such high-risk patients for late acute PJIs.²¹ Our current data suggests that patients with a CRIME80 score ≥ 3 (comprising 21% of the total cohort) will probably benefit more from revision surgery than from DAIR. DAIR was successful in only 35% of these patients, while treatment success increased to 83% when the implant was removed. These results were the same for hips and knees indicating that these joints can be approached the same. However, the causative microorganism and its susceptibility to antibiotics should preferably be taken into account as well, as this clearly affected treatment outcome in our analysis; *S. aureus* was




Fig. 3. Surgical flow chart to determine if a DAIR procedure is feasible or if implant removal should be performed as a first surgical approach. A DAIR procedure is recommended in the Figure when the failure rate of DAIR is $\leq 50\%$, implant removal is advised to be considered if the failure rate of DAIR is $> 50\%$ – 65% , and implant removal is recommended when the failure rate of DAIR exceeds 65% in the studied subcategory.

an independent risk factor for failure in the multivariate analysis, but treatment success was higher when a rifampin based antibiotic regimen was administered.

To decide which percentual a priori chance of failure is acceptable to still recommend a DAIR procedure as a first surgical approach remains a matter of debate, and the advantages of a successful DAIR should be balanced against the consequences of failure. In our study we advised revision surgery if the a priori chance of DAIR failure exceeds more than 65% . It should be taken into account that revision surgery is more aggressive, especially when the implant is well fixed, and is associated with a higher economic burden and longer hospital stay.^{5,8} Although several studies indicated that the success rate of revision surgery applied as salvage therapy after a failed DAIR is very low (ranging between 35% and 58%),^{9,12,18} these low success rates have not been confirmed by others.^{6,14} In our analysis, around 35% of patients who received revision surgery after a failed DAIR procedure experienced pain at the site of the implant during the last outpatient clinic visit, while this was only 16% for those patients in whom revision surgery was performed as a first approach. These results suggest that functional outcome is worse when revision surgery is applied as salvage therapy, but previous studies evaluating several validated functional outcome scores do not support this finding.^{7, 12} Our results do not indicate that applying revision surgery as first approach is not safe. Although not statistically different, in patients with a CRIME80-score ≥ 3 , mortality rate was even higher when patients were treated with DAIR compared to implant removal (8.4% versus 4.2%).

Our results should be interpreted in light of the following limitations. One of the limitations of our study was the retrospective study design with all the well-known limitations and risks for bias. Although we performed 1:1 propensity matching to control

for bias, a randomized controlled trial remains the highest level of evidence in demonstrating the superiority of one treatment over another. In spite of the fact that we did not observe any differences in comorbidity and age between both treatment groups, we cannot completely rule out that a DAIR procedure was chosen based on the clinical judgment of the surgeon and therefore, by definition performed in a selected group of patients with a higher a priori chance to fail. Propensity score matching was only performed in a subset of patients that underwent DAIR (i.e. 24% of the total cohort), imposing the risk that the severely ill patients were excluded from the propensity analysis (i.e. high fever, shorter duration of symptoms), and a DAIR may still be the preferable treatment option in an acute setting for these patients despite a high CRIME80 score. In addition, we do not have data whether the implant was fixed or loosened during revision surgery and/or an osteotomy was necessary to remove the implant. In general, DAIRs are performed in fixed implants, and applying revision surgery in these cases, will lead to more bone destruction when removing the implant compared to loosened prostheses. Although we did not find any differences in functional outcome after revision surgery between cemented and uncemented prostheses, the lack of this information subjects our study to selection bias as well, and propensity matching cannot fully correct for this. Finally, the outcome of DAIR is also determined by the antibiotic regimen that can be administered. In vivo animal models demonstrate the efficacy of rifampin combinations in orthopaedic implant related infections in cases with a low bacterial inoculum and young biofilm.²² In particular the combination of rifampin with a fluoroquinolone has been proven to be a strong predictor of treatment success in patients with staphylococcal PJI.²³ When choosing the surgical strategy for late acute PJI, the causative microorganism

and is susceptibility to antibiotics is often not known, and thus, this factor for predicting the chance of treatment success cannot always be taken into account. All of these limitations should be taken into account when interpreting the results.

In conclusion, DAIR is a viable treatment option in most patients with late acute PJI, but outcome is significantly worse compared to implant removal. In patients with a high CRIME80-score (≥ 3) and in infections caused by *S. aureus* - in particular in those in whom the mobile components cannot be exchanged and in whom a rifampin-based regimen cannot be administered - revision surgery should be considered.

Collaborators

Anne Gougeon, Harold Common, Anne Méheut, Joan Gomez-Junyent, Majd Tarabichi, Aybegum Demirturk, Taiana Ribeiro, Emerson Honda, Giancarlo Polesello, Paul Jutte, Joris Ploegmakers, Claudia Löwik, Guillem Bori, Laura Morata, Luis Lozano, Mikel Mancheño, Fernando Chaves, David Smolders, Phongsakone Inthavong, Adrian Taylor, Marc Digumber, Bernadette Genevieve Pfang, Eduard Tornero, Encarna Moreno, Ulrich Nöth, Cynthia Rivero, Pere Coll, Xavier Crusi, Isabel Mur, Juan Dapás, Pierre Tattévin, Jaime Esteban, Joaquín García-Cañete, Matthew Scarborough.

Conflict of Interest

None.

Acknowledgments

None.

Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi:[10.1016/j.jinf.2019.07.003](https://doi.org/10.1016/j.jinf.2019.07.003).

References

- Aboltins C, Daffy J, Choong P, Stanley P. Current concepts in the management of prosthetic joint infection. *Intern Med J* 2014;**44**(9):834–40.
- Ascione T, Pagliano P, Balato G, Mariconda M, Rotondo R, Esposito S. Oral therapy, microbiological findings, and comorbidity influence the outcome of prosthetic joint infections undergoing 2-stage exchange. *J Arthroplasty* 2017;**32**(7):2239–43.
- Azzam KA, Seeley M, Ghanem E, Austin MS, Purtill JJ, Parvizi J. Irrigation and debridement in the management of prosthetic joint infection: traditional indications revisited. *J Arthroplasty* 2010;**25**:1022–7.
- Boddapati V, Fu MC, Mayman DJ, Su EP, Sculco PK, McLawhorn AS. Revision total knee arthroplasty for periprosthetic joint infection is associated with increased postoperative morbidity and mortality relative to non-infectious revisions. *J Arthroplasty* 2018;**33**(2):521–6.
- Bozic KJ, Ries MD. The impact of infection after total hip arthroplasty on hospital and surgeon resource utilization. *J Bone Joint Surg Am* 2005;**87**(8):1746–51.
- Brimmo O, Ramanathan D, Schiltz NK, Pillai AL, Klika AK, Barsoum WK. Irrigation and debridement prior to a two-stage revision total knee arthroplasty does not increase risk of failure. *J Arthroplasty* 2016;**31**(2):461–4.
- Dzaja I, Howard J, Somerville L, Lanting B. Functional outcomes of acutely infected knee arthroplasty: a comparison of different surgical treatment options. *Can J Surg* 2015;**58**(6):402–7.
- Fisman DN, Reilly DT, Karchmer AW, Goldie SJ. Clinical effectiveness and cost-effectiveness of 2 management strategies for infected total hip arthroplasty in the elderly. *Clin Infect Dis* 2001;**32**(3):419–30.
- Gardner J, Gioe TJ, Tatman P. Can this prosthesis be saved?: implant salvage attempts in infected primary TKA. *Clin Orthop Relat Res* 2011;**469**:970–6.
- Gehrke T, Aljaniipour P, Parvizi J. The management of an infected total knee arthroplasty. *Bone Joint J* 2015;**97**(10 Suppl A):20–9.
- Gundtoft PH, Pedersen AB, Varnum C, Overgaard S. Increased mortality after prosthetic joint infection in primary THA. *Clin Orthop Relat Res* 2017;**475**(11):2623–31.
- Herman BV, Nyland M, Somerville L, MacDonald SJ, Lanting BA, Howard JL. Functional outcomes of infected hip arthroplasty: a comparison of different surgical treatment options. *Hip Int* 2017;**27**(3):245–50.
- Lora-Tamayo J, Murillo O, Iribarren JA, Soriano A, Sanchez-Somolinos M, Barria-Etxaburu JM, et al. A large multicenter study of methicillin susceptible and methicillin-resistant *staphylococcus aureus* prosthetic joint infections managed with implant retention. *Clin Infect Dis* 2013;**56**(2):182–94.
- Nodzo SR, Boyle KK, Nocon AA, Henry MW, Mayman DJ, Westrich GH. The influence of a failed irrigation and debridement on the outcomes of a subsequent 2-stage revision knee arthroplasty. *J Arthroplasty* 2017;**32**(8):2508–12.
- Osmon DR, Berbari EF, Berendt AR, Lew D, Zimmerli W, Steckelberg JM, et al. Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the infectious diseases society of America. *Clin Infect Dis* 2013;**56**(1):1–25.
- Parvizi J, Gehrke T. Definition of periprosthetic joint infection. *J Arthroplasty* 2014;**29**(7):1331.
- Rodríguez D, Pigrau C, Euba G, Cobo J, García-Lechuz J, Palomino J, et al. Acute haematogenous prosthetic joint infection: prospective evaluation of medical and surgical management. *Clin Microbiol Infect* 2010;**16**(12):1789–95.
- Sherrel JC, Fehring TK, Odum S, Hansen E, Zmistowski B, Dennis A, et al. Fate of two-stage reimplantation after failed irrigation and debridement for periprosthetic knee infection. *Clin Orthop Relat Res* 2011;**469**:18–25.
- Tande AJ, Palrai BR, Osmon DR, Berbari EF, Baddour LM, Lohse CM, et al. Clinical presentation, risk factors, and outcomes of hematogenous prosthetic joint infection in patients with *staphylococcus aureus* bacteremia. *Am J Med* 2016;**129**(2):e11–20.
- Vilchez F, Martínez-Pastor JC, García-Ramiro S, Bori G, Tornero E, García E, et al. Efficacy of debridement in hematogenous and early post-surgical prosthetic joint infections. *Int J Artif Organs* 2011;**34**(9):863–9.
- Wouthuyzen-Bakker M, Sebillotte M, Lomas J, Taylor A, Palomares EB, Murillo O, et al. Clinical outcome and risk factors for failure in late acute prosthetic joint infections treated with debridement and implant retention. *J Infect* 2019;**78**(1):40–7.
- Zimmerli W, Sendi P. Role of rifampin against staphylococcal biofilm infections in vitro, in animal models, and in orthopedic device related infections. *Antimicrob Agents Chemother* 2019;**63**(2):e01746–18, 1–10.
- Zimmerli W, Widmer AF, Blatter M, Frei R, Ochsner PE, et al. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. *JAMA* 1998;**279**:1537–41.